These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 30474439

  • 1. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.
    Zhang J, Rössle M, Zhou X, Deng J, Liu L, Qi X.
    Curr Med Res Opin; 2019 May; 35(5):859-868. PubMed ID: 30474439
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Research progress of terlipressin in the treatment of cirrhotic ascites-related complications].
    Liu CH, Xing F, Wang J.
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec 20; 27(12):929-932. PubMed ID: 31941255
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
    Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU.
    United European Gastroenterol J; 2019 May 20; 7(4):529-537. PubMed ID: 31065370
    [Abstract] [Full Text] [Related]

  • 6. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
    Duong N, Kakadiya P, Bajaj JS.
    Clin Gastroenterol Hepatol; 2023 Sep 20; 21(10S):S27-S34. PubMed ID: 37625864
    [Abstract] [Full Text] [Related]

  • 7. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Garcia-Tsao G, Abraldes JG, Rich NE, Wong VW.
    Gastroenterology; 2024 Jan 20; 166(1):202-210. PubMed ID: 37978969
    [Abstract] [Full Text] [Related]

  • 8. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA, Sharma P, Sanyal AJ, Mayo MJ, Frederick RT, Escalante S, Jamil K, CONFIRM Study Investigators.
    N Engl J Med; 2021 Mar 04; 384(9):818-828. PubMed ID: 33657294
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
    Carter JA, Huang X, Jamil K, Corman S, Ektare V, Niewoehner J.
    J Med Econ; 2023 Mar 04; 26(1):1342-1348. PubMed ID: 37729445
    [Abstract] [Full Text] [Related]

  • 10. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
    Wong F, Pappas SC, Boyer TD, Sanyal AJ, Bajaj JS, Escalante S, Jamil K, REVERSE Investigators.
    Clin Gastroenterol Hepatol; 2017 Feb 04; 15(2):266-272.e1. PubMed ID: 27464593
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
    Nanda A, Reddy R, Safraz H, Salameh H, Singal AK.
    J Clin Gastroenterol; 2018 Apr 04; 52(4):360-367. PubMed ID: 28991106
    [Abstract] [Full Text] [Related]

  • 12. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC, REVERSE Study Investigators.
    Gastroenterology; 2016 Jun 04; 150(7):1579-1589.e2. PubMed ID: 26896734
    [Abstract] [Full Text] [Related]

  • 13. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.
    Sharma P, Moore K, Ganger D, Grewal P, Brown RS.
    Liver Transpl; 2020 Oct 04; 26(10):1328-1336. PubMed ID: 32574418
    [Abstract] [Full Text] [Related]

  • 14. Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies.
    Curry MP, Vargas HE, Befeler AS, Pyrsopoulos NT, Patwardhan VR, Jamil K.
    Hepatol Commun; 2023 Jan 01; 7(1):e1307. PubMed ID: 36633470
    [Abstract] [Full Text] [Related]

  • 15. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
    Huang X, Bindra J, Chopra I, Niewoehner J, Wan GJ.
    Adv Ther; 2023 Dec 01; 40(12):5432-5446. PubMed ID: 37812332
    [Abstract] [Full Text] [Related]

  • 16. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H, Chawla Y.
    J Gastroenterol Hepatol; 2011 Jan 01; 26 Suppl 1():109-14. PubMed ID: 21199521
    [Abstract] [Full Text] [Related]

  • 17. Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.
    Allegretti AS, Subramanian RM, Francoz C, Olson JC, Cárdenas A.
    Liver Int; 2022 Oct 01; 42(10):2124-2130. PubMed ID: 35838488
    [Abstract] [Full Text] [Related]

  • 18. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P, Kumar A, Shrama BC, Sarin SK.
    Am J Gastroenterol; 2008 Jul 01; 103(7):1689-97. PubMed ID: 18557715
    [Abstract] [Full Text] [Related]

  • 19. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
    Solà E, Cárdenas A, Ginès P.
    Curr Opin Organ Transplant; 2013 Jun 01; 18(3):265-70. PubMed ID: 23652609
    [Abstract] [Full Text] [Related]

  • 20. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
    Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL.
    Cochrane Database Syst Rev; 2017 Sep 27; 9(9):CD011532. PubMed ID: 28953318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.